Institutional Investors completed the acquisition of a 20% stake in Regeneron, an American biotechnology company, from Sanofi, a global biopharmaceutical company focused on human health, for $5bn. “The decision to divest our holdings is consistent with our efforts to enhance value creation for our shareholders. We believe the proceeds from this transaction will help further our ability to execute on our strategy to drive innovation and growth,” Paul Hudson, Sanofi CEO.